希罗达联合艾素治疗晚期乳腺癌的临床观察

Clinical observation on docetaxel combined with xeloda in treatment of advanced breast cancer

目的:研究希罗达联合艾素方案治疗晚期乳腺癌的近期疗效及毒副反应。方法:51例晚期乳腺癌患者,均经病理组织学证实。治疗方案希罗达1250mg/m2日两次口服d1～14,艾素35mg/m2静脉滴注d1,8,21天1周期,至少2周期评价疗效。结果:51例中完全缓解(CR)3例,部分缓解(PR)22例,无变化(NC)16例,进展(PD)10例,总有效率(RR)49.01%,1年生存率78.26%。毒副反应主要为骨髓抑制,消化道反应,可耐受。结论:希罗达联合艾素治疗晚期乳腺癌疗效肯定,毒副反应小,是治疗晚期乳腺癌较好方案,值得临床推广。

To evaluate the efficacy and toxicity of docetaxel combined with xeloda in the treatment of patients with advanced breast cancer. Methods： Fifty - one patients with advanced breast cancer diagnosed pathologically were enrolled into the study. The patients received xeloda 2500mg/m^2 , on day 1 - 14 ; and docetaxel 35mg/m^2 ,on day 1,8. The chemotherapy was repeated every 21 days. All the patients received at least 2 cycles. Resuits： Objective response was obtained in 49.01% of patients（ 3 complete and 22 partial responses） whereas 16 patients had no change and 10 patients were progressive,and 1 - year survival rate was 78.26%. The main toxicities included myelosuppression ,nausea, vomiting . Conclusion： Docetaxel combined with xeloda is effective in the treatment of advanced breast cancer , with mild or moderate side effects.